Chief Marketing Officer — Quality And Supply Network

The mandate

A research-led pharmaceutical enterprise is preparing selected brands for divestment from a quality-and-supply network whose external identity has historically been unified. Customers, healthcare professionals, distributors and suppliers will need precise communication about ownership, availability and quality contacts without creating confusion or premature disclosure. The board has planned a new CMO seat to lead trust through separation.

Approximately 550 employees and material partners support brand, communication, quality, supply, market and partner activity from Copenhagen across international markets. The CMO owns brand architecture, stakeholder communication, corporate reputation, channel governance, insight and marketing operations, reporting to the Group Chief Executive or nominated sponsor. Quality, medical and regulatory functions approve matters within their authority.

The first task is a stakeholder-and-obligation map. Each audience needs different information at different times. Distributors require ordering and complaint routes; healthcare professionals need product and medical continuity; suppliers need instruction authority; patients need clarity without transaction detail. The CMO will align communication gates with legal and operational readiness.

Brand architecture must survive ownership transition. Product names, corporate marks, packaging, digital domains, materials and market registrations may change on different timetables. The CMO will define temporary coexistence, licence and withdrawal rules. Legacy identity cannot remain informally because teams are reluctant to retire familiar materials.

Quality communication deserves discipline. Shortage, defect, recall or complaint messaging requires facts, authorised review and traceability. The CMO will establish rapid routes without allowing reputation concerns to delay essential information. Public statements should distinguish known fact, precaution and investigation.

Supply continuity claims must match operations. Customers may seek reassurance during divestment, but unconditional promises can mislead when inventory, transfer or approvals remain uncertain. The CMO will use scenario-approved messages, update them when evidence changes and give teams clear escalation for market-specific questions.

Promotional content separation requires inventory and rights. Materials may cover retained and divested products, use shared data or involve contracted agencies. The CMO will ensure ownership, evidence, consent, localisation and expiry are mapped. Buyer access will be controlled, and non-transferring content removed from copied libraries.

Digital channels carry hidden dependencies. Websites, social accounts, email domains, consent preferences and search listings may continue after legal transfer. The CMO will create redirect, archive, ownership and monitoring plans. A transferred brand must not leave patient or adverse-event messages in an unmonitored legacy inbox.

Agency governance will span both parties. Creative, media, public relations and market-research firms need revised scope, confidential information boundaries and data instructions. Clean-team constraints will apply where competition rules require. Agencies must confirm return or deletion of material they no longer have authority to hold.

Stakeholder insight should anticipate confusion. The CMO will test communication with representative users where lawful, ensuring language, accessibility and local context. Research cannot reveal the transaction prematurely or collect sensitive information without proper purpose.

Employee communication supports external trust. Teams need to know what they may say and where questions go. The CMO will coordinate with people and transaction leaders, avoiding vague scripts that invite improvisation. Frontline quality and customer staff should receive scenario practice before public milestones.

Reputation monitoring will distinguish ordinary sentiment from product or safety signals. Social and media concerns will route to quality, medical, safety or legal owners promptly. The marketing team should not resolve such issues through public reassurance alone. Records and response decisions will be retained.

The future retained organisation also needs a coherent identity. Divestment can leave a confusing portfolio narrative and duplicated channels. The CMO will define the retained brand proposition and remove stranded marketing cost without losing necessary stakeholder routes.

What you will own

• Divestment brand and stakeholder communication.
• Audience, timing and approval architecture.
• Product identity, content and channel separation.
• Quality, shortage and continuity communication.
• Agency, digital, consent and data transition.
• Employee communication readiness.
• Reputation monitoring and issue routing.
• Retained marketing model and talent.

The first 12 months

Within 45 days, inventory stakeholders, channels and content, identify orphaned contacts and agree communication gates. Protect any product or quality route at immediate risk.

By month six, complete brand and digital separation design, prepare market communication packs and validate agency and inbox ownership. Train frontline teams through scenarios.

At twelve months, achieve 100% controlled transfer or retirement of in-scope content and channels, with no unmonitored product, complaint or safety contact. Ninety-five per cent of priority stakeholders should receive accurate communication within agreed windows, while retained marketing cost falls 15% without a material trust or service lapse.

What the sponsor will examine

• Audiences receiving only timely, useful information.
• Brand rights and coexistence explicitly controlled.
• Quality communication outranking reputation comfort.
• Supply claims changing with operational evidence.
• Digital channels retaining accountable monitoring.
• Retained identity coherent after separation.

The person

You bring 22–28 years in pharmaceutical marketing, corporate affairs or brand leadership, including CMO authority through a divestment, product transfer or major portfolio change. Your record includes regulated content, quality communication and multi-market stakeholder management.

Candidates must show a communication they delayed for confidentiality and another they accelerated for patient or product safety. Copenhagen is the hybrid base, with international market engagement.

Compensation and terms

Base compensation is DKK 2,550,000–3,500,000 plus annual incentive and long-term participation linked to trusted separation, channel control, stakeholder continuity, retained value and leadership. The permanent hybrid appointment is anchored in Copenhagen and accountable to the Group Chief Executive or designated executive-committee sponsor. Planned timing precedes public transaction milestones.

Confidentiality

The enterprise, brands, products, quality matters, buyers, suppliers, customers and communication plans remain confidential. Further information follows conflicts and signed confidentiality. Applicants must not contact companies, agencies or media to determine the client.